Japan Society of Clinical Trials and Research ( JPT Supplement )

Vol. 47 Suppl. 2 2019

Explanatory Commentary on the Contract Template for Investigator-initiated Multicenter
Clinical Trials Adapting the Clinical Trials Act in Japan

G. Kawahira

Jpn Pharmacol Ther 2019; 47 (s2) : s114-7.

Relationships with Pharmaceutical Companies in the Clinical Trials Act
──Development of RACI chart

M. Mori

Jpn Pharmacol Ther 2019; 47 (s2) : s118-21.

To Operate the Clinical Trials Act Properly
　 (Consideration of Collaborative Clinical Research)

H. Asai

Jpn Pharmacol Ther 2019; 47 (s2) : s122-5.

Study Design and Analysis Methods in Clinical Trials with Genomic Biomarkers

S. Nomura

Jpn Pharmacol Ther 2019; 47 (s2) : s126-8.

Overview of Research Nurses

N. Fujiwara

Jpn Pharmacol Ther 2019; 47 (s2) : s129-31.

Possibility of Collaboration between Research Nurse and Clinical Research Coordinator

Y. Yanagisawa

Jpn Pharmacol Ther 2019; 47 (s2) : s132-3.

Preparation of Standard Operating Procedures Reflected the Latest Information for Investigator-initiated Clinical Trials

H. Hayashi,et al

Jpn Pharmacol Ther 2019; 47 (s2) : s134-47.

Analysis of the Status of Specified Clinical Trials Using jRCT
(Japan Registry of Clinical Trials)

H. Taruno, et al

Jpn Pharmacol Ther 2019; 47 (s2) : s148-58.

Cross-sectional Survey on Key Knowledge and Skills for Evidence Creation in Pharmaceutical Industry

S. Asada, et al

Jpn Pharmacol Ther 2019; 47 (s2) : s159-65.

Case Report of Kanazawa University Hospital:
Protocol Sample and Checklist Adapted to Clinical Trials Act

N. Horikawa, et al

Jpn Pharmacol Ther 2019; 47 (s2) : s166-73.

Points to Consider for Implementation of Clinical Trials Act: A Case Study at Shiga University of Medical Science Research Ethics Committee

M. Kurata, et al

Jpn Pharmacol Ther 2019; 47 (s2) : s174-9.

Inquiry about the Physician-initiated Clinical Trial with iPS Cells for Parkinson's Disease:
Evaluation of the Role of a Call Center

A. Kawakami, et al

Jpn Pharmacol Ther 2019; 47 (s2) : s180-6.